Approval · Notice of Compliance 23798 · 2020
JAMP RIZATRIPTAN: Notice of Compliance 23798
Issued June 15, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23798
- Date
- June 15, 2020
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Companies. & Administrative: Product Name Change.
- Canadian reference product
- MAXALT
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JAMP RIZATRIPTAN | 02380455 | Dormant |
| JAMP RIZATRIPTAN | 02380463 | Marketed |
Medicinal ingredients
- RIZATRIPTAN BENZOATE 5 MG per TAB
- RIZATRIPTAN BENZOATE 10 MG per TAB